Price Chart

Price Chart

Profile

MetaVia, Inc. is a clinical-stage biotechnology company, which engages in developing novel pharmaceuticals to treat cardiometabolic diseases. It is developing DA-1726 for the treatment of various cardiometabolic conditions, with potential in both Metabolic and Alcohol-Associated Liver Disease (MetALD) and Alcohol-Associated Liver Disease (ALD), and is advancing vanoglipel (DA-1241) in combination with resmetirom for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). The company was founded on October 30, 2014 and is headquartered in Cambridge, MA.
URL http://metaviatx.com
Investor Relations URL https://www.metaviatx.com/investor-overview
HQ State/Province Massachusetts
Sector Health Care
Industry Biotechnology
Equity Style Small Cap Value
Next Earnings Release N/A
Last Earnings Release N/A
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

MetaVia, Inc. is a clinical-stage biotechnology company, which engages in developing novel pharmaceuticals to treat cardiometabolic diseases. It is developing DA-1726 for the treatment of various cardiometabolic conditions, with potential in both Metabolic and Alcohol-Associated Liver Disease (MetALD) and Alcohol-Associated Liver Disease (ALD), and is advancing vanoglipel (DA-1241) in combination with resmetirom for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). The company was founded on October 30, 2014 and is headquartered in Cambridge, MA.
URL http://metaviatx.com
Investor Relations URL https://www.metaviatx.com/investor-overview
HQ State/Province Massachusetts
Sector Health Care
Industry Biotechnology
Equity Style Small Cap Value
Next Earnings Release N/A
Last Earnings Release N/A
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A